Background and aims: Myofibroblast hyperplasia contributes to muscularis mucosae thickening and stricture formation
Introduction
Formation of strictures, leading to intestinal obstruction, is a common clinical problem in Crohn's disease (CD). Overgrowth and thickening of the muscularis mucosae is frequently seen in CD, and contributes to the stricture formation. 1, 2 The expansion of muscularis mucosae is associated with an increased number of myofibroblasts, possibly as a result of transdifferentiation and proliferation of resident smooth muscle cells in this layer. 3, 4 Protease-activated receptor-2 (PAR-2) is a G-protein coupled receptor that is activated upon proteolytic cleavage by specific serine proteases, such as trypsin and mast cell tryptase. 5 PAR-2 is expressed by various different cell types in the intestine of mammals, [6] [7] [8] [9] [10] including intestinal myofibroblasts. 11 PAR-2 activation has been shown to increase normal cell proliferation, [12] [13] [14] [15] and to augment growth of tumor cells. 16, 17 However, the significance of PAR-2 in regulating growth of intestinal myofibroblasts has never been investigated.
CD is associated with a diminished intestinal epithelial barrier to macromolecules, 18, 19 and it seems likely, thus, that increased amounts of luminal trypsin may cross the bowel wall in CD. Moreover, activation of intestinal mast cells is a feature of CD, 20 and activated mast cells are known to release large amount of the PAR-2 activator tryptase. 21 Taken together, there are reasons to believe that CD is associated with an increased content of PAR-2 activating proteases in the bowel wall. In addition, CD is associated with increased concentrations of tumor necrosis factor-α (TNF-α) in the intestinal mucosa. 22, 23 It is widely accepted that this cytokine is a major mediator in the pathophysiology of CD, and anti-TNF-α therapy is highly effective in the clinical management of CD. 24 TNF-α has been shown to up-regulate PAR-2 expression in experimental studies. 25, 26 One may speculate, thus, that such a possible PAR-2 up-regulation in CD might render cells of the bowel mucosa more responsive to PAR-2-mediated activation by proteases.
Activation of phospholipase A 2 (PLA 2 ) and production of arachidonic acid (AA) metabolites have been implicated in the pathophysiology of various inflammatory diseases, including CD, 27, 28 and also in the regulation of cell growth. [29] [30] [31] It has been reported that stimulation of PAR-2 may activate intracellular, high-molecular weight, PLA 2 s, [32] [33] [34] [35] [36] and PAR-2-stimulated proliferation has been associated with an increased production of AA metabolites in some studies. 13, 14, 17, 37 Indeed, there are several lines of evidence that PAR-2 may regulate normal intestinal processes, such as motility and secretion, via the production of AA metabolites. 38 It is still unknown, however, if PLA 2 activation affects intestinal myofibroblast proliferation, and if PAR-2 stimulation activates PLA 2 in this cell type.
Increased levels of several AA metabolites in the CD intestine positively correlate with disease activity, and it is generally accepted that AA metabolites are involved in the pathophysiology of CD (for reviews see Eberhart, 39 Mohajer 40 and Wang 41 ). Most mammalian cells express two main types of intracellular, high-molecular weight, PLA 2 s, commonly named cytosolic PLA 2 (cPLA 2 ) and Ca 2+ -independent PLA 2 (iPLA 2 ). 42 However, cPLA 2 is the only PLA 2 type that shows selectivity toward AA, 43 and it is generally believed, therefore, that cPLA 2 plays a key role in the biosynthesis of AA metabolites. 43 No studies concerning PLA 2 activity in intestinal myofibroblasts have been reported, and the relative contribution of different PLA 2 types in the release of AA in this cell type remains to be investigated.
The principal aim of the present study was to obtain further information about cellular mechanisms involved in the myofibroblast hyperplasia of the muscularis mucosae in CD strictures. Based on the obtained results, we hypothesize that TNF-α -induced PAR-2 up-regulation and PAR-2-mediated cPLA 2 activation might be of importance in intestinal myofibroblast proliferation.
Material and methods

Intestinal tissue samples
Full-thickness ileal specimens with microscopically established muscularis mucosae overgrowth were obtained from four patients (three men and one woman, 36-56 years, mean 47) operated on for Crohn's ileitis at the university hospital of Linköping. All specimens were taken from macroscopically normal mucosa, but specimens from one of the patients showed signs of microscopic inflammation (neutrophil infiltration). At the time of operation, one of the patients was on medication with azathioprine, and one (the one with microscopically inflamed mucosa) was on medication with mesalasine. Fullthickness specimens of normal ileum were obtained from five patients operated on for colonic cancer (four women and one man, 70-92 years, mean 81), and used as comparative controls. Specimens were snap frozen, cryosectioned in 4 μm slices, and analyzed for PAR-2 by immunohistochemistry. The study was approved by the ethics committee of research on human subjects (the regional ethical review board in Linköping), and carried out in accordance with the Declaration of Helsinki.
Cells
The human cell line CCD-18Co (ATCC, no. CRL-1459) was obtained from LGC Promochem (Middlesex, UK). CCD-18Co cells exhibit many of the known characteristics of intestinal myofibroblasts, 44 and were cultured as previously described. 44 Cell viability was routinely determined by the trypan blue exclusion assay, and was not affected by the different treatments used. However, to maintain the viability of the cells, the concentrations of some agents had to be adjusted depending on the experimental layout (i.e. in the studies on proliferation, the concentration of trypsin had to be lowered because of the relatively long incubation time, and the concentration of AACOCF 3 had to be lowered because of an increased toxicity of this substance during serum-free conditions). If not otherwise indicated, pre-confluent cells were used for the studies.
Stimulation of PAR-2 expression
Cells were seeded in culture dishes (20 cm 2 ) or on chamber slides (0.8 cm 2 ; Nalge Nunc International, Rochester, NY), and cultured for up to 72 h with TNF-α (25 ng/ml). Cells in dishes were analyzed for PAR-2 by RT-PCR, whereas cells on chamber slides were supplied to immunocytochemical analysis.
RT-PCR
Hexamer-primed cDNA was generated (Omniscript reverse transcript RT Kit, Qiagen, Solna, Sweden) from 500 ng isolated total RNA (Ultraspec II RNA isolation system, Nordic BioSite, Täby, Sweden) and amplified using PuReTaq RTG PCR beads (Amersham Biosciences, GE Healthcare, Freiburg, Germany) and primers (Invitrogen Life Technologies Ltd, Paisley, UK) specific for human PAR-2 (forward, 5′-CTG CAT CTG TCC TCA CTG GA; reverse, 5′-GAC ACT TCG GCA AAG GAG AG; product size, 899 bp) or 18SrRNA (forward, 5′-ACG RAC CAG AGC GAA AGC AT; reverse, 5′-GGA CAT CTA AGG GCA TCA CAG AC; product size 531 bp). 45 Two amplification programs for PAR-2 were used, either 1 cycle 94°C, 5 min; followed by 45 cycles of 94°C, 30 s; 50°C, 1 min; 72°C, 2 min; and a final cycle of 72°C, 15 min, or (for semi-quantitative evaluation after TNF-α stimulation) 1 cycle 94°C, 2 min; followed by 45 cycles of 94°C, 30 s; 58°C, 30 s; 72°C, 1.5 min; and a final cycle of 72°C, 10 min. The amplification program for 18SrRNA was: 1 cycle 94°C, 2 min; followed by 20 cycles of 94°C, 20 s; 58°C, 20 s; 72°C, 45 s; and a final cycle of 72°C, 5 min. The PCRproducts were identified by size after gel electrophoresis. The identity of the PAR-2 product was also verified by sequencing (MWG Biotech AG, Martinsried, Germany). Caco-2 cells were used as positive control for PAR-2 16 , and untranscribed total RNA was used as negative control.
Immunohistochemistry and immunocytochemistry
Cryosections (fixed in ice-cold acetone) and cells on chamber slides (fixed in 4% paraformaldehyde) were incubated with mouse anti-human PAR-2 monoclonal antibody (FITC-conjugated SAM-11, diluted 1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4°C for 16 h. Before incubation, cryosections were blocked with 50% normal rabbit serum (DakoCytomation, Glostrup, Denmark) for 1 h at room temperature. An isotype-matched, irrelevant, mouse IgG 2a antibody (DakoCytomation) was used as negative control. After incubation with the irrelevant antibody (not FITC-conjugated) a secondary, biotin-conjugated, rabbit anti-mouse antibody (DakoCytomation) and FITC-conjugated streptavidin (DakoCytomation) were added. For visualization of cells on chamber slides, actin filaments were stained with rhodamine-phalloidin (Molecular Probes, Eugene, OR, USA). Slides were examined using NikonEclipse E600 Confocal Microscope (Nikon, Japan) and Nikon Confocal Microscope EZ-C1 Software version 2.0.
Release of AA
Cells seeded in 20 cm 2 culture dishes were labeled for 24 h with 0.1 μCi 14 C-labeled arachidonic acid ( 14 C-AA) (Amersham Biosciences, GE Healthcare, Freiburg, Germany) as described, 46 before treated with appropriate stimulators and inhibitors for various times and concentrations. If cells were pre-treated with TNF-α, this cytokine was added to the growing cells for 48 h, before new medium with TNF-α and 14 C-AA was added for further 24 h. All treatments of 14 C-labeled cells with stimulators and inhibitors were done in the absence of serum. The amount of 14 C-AA released to the culture medium was analyzed by liquid scintillation counting. Trypsin (type IX-S from porcine pancreas) and the peptide SLIGRL-NH 2 47 (Peptides International, Louisville, KY, USA) were used as PAR-2 activators. Methyl arachidonyl fluorophosphonate (MAFP) was used as combined inhibitor of cPLA 2 and iPLA 2 , 48 whereas bromoenol lactone (BEL) was used as a specific inhibitor of iPLA 2 . 48 Phorbol myristate acetate (PMA) and the calcium ionophore A23187 were used to specifically stimulate cPLA 2 -mediated AA release. The specificity for AA was verified by a comparable stimulation of 14 C-oleic acid (New England Nuclear, Perkin Elmer, Wellesley, MA, USA) labeled cells. If not otherwise indicated, all stimulators and inhibitors were obtained from Sigma (St. Louis, MO, USA).
Cell proliferation
Cells seeded in 9 cm 2 culture dishes were incubated with the combined cPLA 2 and iPLA 2 inhibitor 48 AACOCF 3 (10 μM) or the specific iPLA 2 inhibitor 48 BEL (10 μM) for 3 days, before pulselabeled for 4 h with 0.4 μCi 3 H-thymidine (Amersham Biosciences, GE Healthcare, Freiburg, Germany). The amount of incorporated radioactivity was analyzed as described. 49 Unlabeled cells in parallel dishes were counted in a haemocytometer.
Cells seeded in 20 cm 2 culture dishes were serum-starved for 2 days, before the PAR-2 activator trypsin (type IX-S from porcine pancreas) (1 nM), with or without 5 μM AACOCF 3 , was added. After 5 days with trypsin, and or AACOCF 3 , cells were counted in a haemocytometer.
Trypsin and PLA 2 inhibitors were obtained from Sigma. AACOCF 3 was used instead of MAFP in the studies on proliferation to avoid possible oxidative inactivation of MAFP 50 during the relatively long incubation times used in these experiments.
Statistical analysis
Values are given as mean ± SEM. GraphPad Prism 4.0 software (GraphPad Software, San Diego, CA, USA) was used for statistical evaluations. Depending on the experimental layout, data was analyzed by, one-way ANOVA and StudentNewman-Keul test, or repeated measures ANOVA and Student-Newman-Keul test.
Results
PAR-2 immunolabelling of the ileal mucosa
Mucosal PAR-2 immunolabelling was, as expected from previous studies, [6] [7] [8] [9] [10] [11] found in the epithelium and scattered through the lamina propria both in CD patients and controls ( Fig. 1a and b) . The PAR-2 immunolabelling was, however, very strongly expressed in the expanded muscularis mucosae of the CD specimens (Fig. 1b) .
TNF-α, known to be present at increased levels in the CD mucosa, has been reported to up-regulate PAR-2 in some cell types. Our next step was, therefore, to investigate if the PAR-2 expression of intestinal myofibroblast may be affected by this inflammatory cytokine.
TNF-α stimulates PAR-2 mRNA expression in intestinal myofibroblasts
The myofibroblast cell line CCD-18Co was found to express a basal level of PAR-2 mRNA (Fig. 2a) . This expression was evident in both pre-confluent, proliferating cells, and in confluent cells that had reached mitotic silence (Fig. 2a) .
To simplify the detection of any increased PAR-2 mRNA expression after TNF-α stimulation, the PCR-reaction was adjusted so that the basal expression was just below the detection limit. Stimulation with TNF-α increased the PAR-2 mRNA expression, and this increase was time-dependent, being more obvious after 48 h than after 24 h of stimulation (Fig. 2b) . Moreover, the effect of TNF-α on the PAR-2 mRNA expression seemed to be more pronounced in pre-confluent cells, than in confluent cells (Fig. 2b) .
Since only the use of pre-confluent cells is scientifically justified when studying cellular events related to proliferation, only pre-confluent CCD-18Co cells were used in the subsequent studies.
TNF-α stimulates PAR-2 protein expression in intestinal myofibroblasts
PAR-2 was detected upon immunocytochemical analysis of untreated control cells, and the expression was increased in cells stimulated with TNF-α (Fig. 3) .
Because of our finding that PAR-2 was up-regulated by TNF-α, together with the reported ability of PAR-2 activators to stimulate intracellular PLA 2 activity in other cell types, we next investigated if up-regulation of PAR-2 by TNF-α affected AA mobilization in intestinal myofibroblasts.
TNF-α potentiates PAR-2-stimulated AA release in intestinal myofibroblasts
The PAR-2 activator trypsin caused a dose-dependent increase in the basal release of AA (Fig. 4) . Pre-incubation with 10-100 ng/ml TNF-α for 72 h was without effect on the basal release of AA, but significantly potentiated the trypsinstimulated AA release (Fig. 5a ). This effect by TNF-α was independent of dose within the studied range (Fig. 5a ). On the other hand, the trypsin-stimulated AA release after preincubation with 100 ng/ml TNF-α was dependent on the trypsin dose (Fig. 5b) .
Like trypsin, the specific PAR-2 activating peptide, SLIGRL-NH 2 , significantly increased the AA release from TNF-α -treated cells (Fig. 5c) , although it was unable to release AA per se at the concentration used in this study (Fig. 5c) .
The release of AA after trypsin-stimulation of TNF-α -treated cells was reduced by pre-treatment with MAFP, a combined inhibitor of cPLA 2 and iPLA 2 (Fig. 6a) , but not by the specific iPLA 2 inhibitor BEL (Fig. 6b) .
Since TNF-α per se is a known stimulator of cPLA 2 expression and activity in many cells, we next investigated if the synergism between TNF-α and trypsin could merely be explained by TNF-α -mediated stimulation of cPLA 2 .
TNF-α alone does not affect cPLA 2 -mediated release of AA in intestinal myofibroblasts
The protein kinase C stimulator PMA and the calcium ionophore A23187 were found to synergistically increase the release of AA, but not the release of the control fatty acid, 14 C-oleic acid, (Fig. 7a) . Moreover, this synergistic effect was reduced by MAFP (Fig. 7b) . These results suggest that the AA release after combined stimulation with PMA and A23187 was due to the activation of an AA specific, intracellular, high-molecular weight PLA 2 , that was dependent on both phosphorylation and an increased intracellular calcium level for its activity, i.e. cPLA 2 . 43 Pre-incubation of the cells with TNF-α, according to the same protocol as used in the experiments on trypsin-stimulated AA release, did not affect this cPLA 2 -mediated AA release (Fig. 7c) .
Our finding that PAR-2 stimulation activates cPLA 2 in intestinal myofibroblasts, prompted us to investigate if PAR- 2 stimulation and cPLA 2 was of importance in the regulation of intestinal myofibroblast growth.
cPLA 2 activity and PAR-2 activation affects intestinal myofibroblast growth
Incubation with the combined cPLA 2 and iPLA 2 inhibitor, AACOCF 3 , but not the specific iPLA 2 inhibitor, BEL, reduced the incorporation of 3 H-thymidin per cell (Fig. 8a) , i.e. the rate of DNA synthesis.
Stimulation of serum-starved cells for 5 days with 1 nM trypsin caused a 25% increase in cell number, compared to unstimulated control cells (Fig. 8a) . This growth-promoting effect of trypsin was abolished in the presence of AACOCF 3 (Fig. 8b) .
Discussion
Morphological and biochemical characterization of cells in the thickened muscularis mucosae have indicated that myofibroblasts, rather than conventional smooth muscle cells, are responsible for the overgrowth of this layer in CD, 3, 4 and thereby important in the formation of intestinal strictures. In the present study, strong expression of PAR-2 was demonstrated in the thickened muscularis mucosae from all four CD patients. We therefore hypothesized that the expansion of muscularis mucosae in CD is associated with proliferation of PAR-2 expressing myofibroblasts.
The present study is the first to demonstrate that TNF-α may up-regulate PAR-2 expression and potentiate PAR-2-stimulated AA mobilization in intestinal myofibroblasts, thereby suggesting a novel mechanism of myofibroblast proliferation in intestinal inflammation. Increased amounts of TNF-α are found in the CD mucosa, 22, 23 even in endoscopic normal tissue. 23 In addition, the concentrations of PAR-2 activating proteases, such as trypsin and tryptase, 5 are likely to be increased, because of a diminished epithelial barrier 18, 19 and increased mast cell activation. 20 It seems possible, thus, that TNF-α may up-regulate PAR-2 on intestinal myofibroblasts, and that this, together with increased levels of proteases in the bowel wall, may result in increased PAR-2-mediated myofibroblast activation in CD. The stimulatory effect of TNF-α on PAR-2 expression in intestinal myofibroblasts agrees with previous studies, showing up-regulation of PAR-2 in response to inflammatory cytokines 25, 26 and in various inflammatory conditions. 9, 51, 52 It is worth noticing, however, that up-regulation of PAR-2 by TNF-α is not the only possible connection between TNF-α and PAR-2 in intestinal myofibroblasts. Indeed, intestinal myofibroblasts express TNF-α 53 and PAR-2 activation has been shown to stimulate the release of TNF-α from other cell types. 9, 54 It is quite possible, thus, that stimulation of PAR-2 may release TNF-α also from intestinal myofibroblasts, although this remains to be investigated.
TNF-α and PAR-2 stimulators, including trypsin and a specific PAR-2 stimulator, SLIGRL-NH 2 , 47 were found to synergistically increase the AA release from intestinal myofibroblasts. The trypsin effect was reduced by MAFP, a combined inhibitor of cPLA 2 and iPLA 2 , 48 but not by the specific iPLA 2 inhibitor BEL. 48 It seems likely, thus, that prestimulation with TNF-α up-regulates PAR-2 and that subsequent stimulation with trypsin results in amplification of cPLA 2 -mediated AA release. The synergism between TNF-α and trypsin was dose-dependent with regard to trypsin, but not with regard to TNF-α. It is possible that this was due to a maximal up-regulation of PAR-2 expression already at the lowest TNF-α concentration used, and that the AA release was only dependent on the degree of receptor stimulation.
Stimulation with SLIGRL-NH 2 without previous TNF-α stimulation did not cause any release of AA. It is known that SLIGRL-NH 2 has much lower potency compared to protease-mediated activation. 55 Obviously, the concentration of SLIGRL-NH 2 used in our study was not high enough to activate the cells, unless the amount of PAR-2 receptors was up-regulated by previous stimulation by TNF-α. TNF-α is a known activator of cPLA 2 expression and activity, 56, 57 suggesting that the synergism between TNF-α and trypsin was due to TNF-α -mediated stimulation of cPLA 2 . However, TNF-α did not affect the cPLA 2 -mediated AA release induced by PMA and A23187. It seems more likely, thus, that the synergism between TNF-α and trypsin was due to up-regulation of PAR-2.
A number of studies have demonstrated that PAR-2 stimulation may activate intracellular high-molecular weight PLA 2 s. [32] [33] [34] [35] [36] However, the apparent selectivity for either iPLA 2 32,33,35 or cPLA 2 36 in some studies, suggests that the coupling between PAR-2 and a particular PLA 2 -isosyme may vary among cell types. The present study suggests that PAR-2 is linked to cPLA 2 in intestinal myofibroblasts. This was not due to an absence of iPLA 2 expression, since we have previously seen that CCD-18Co cells have a basal expression of both iPLA 2 and cPLA 2 (U Christerson, unpublished results). The precise cellular mechanisms involved in PAR-2-stimulated cPLA 2 activation in intestinal myofibroblasts remain to be investigated. However, activation of PAR-2 stimulates intracellular Ca 2+ mobilization and activation of mitogenactivated protein kinases in several cell types, events known to be of importance in the regulation of cPLA 2 activity. 43 cPLA 2 activity 30, 31 have previously been linked to cellular proliferation. Therefore, our finding that PAR-2 stimulation activated both cPLA 2 and proliferation in intestinal myofibroblasts, prompted us to investigate if this intracellular highmolecular weight PLA 2 is involved in the regulation of intestinal myofibroblast growth. AACOCF 3 , a combined cPLA 2 and iPLA 2 inhibitor, 48 but not the specific iPLA 2 inhibitor BEL, 48 was found to reduce the rate of DNA synthesis (i.e. incorporation of 3 H-thymidin/cell in pulse-labeled cells). Moreover, AACOCF 3 abolished the trypsin-stimulated proliferation. Taken together, thus, it seems possible that cPLA 2 may have a role in PAR-2 stimulated intestinal myofibroblast growth.
In conclusion, this study demonstrates (i) that PAR-2 is strongly expressed in the expanded muscularis mucosae in CD, (ii) that TNF-α may up-regulate the PAR-2 receptor and increase PAR-2-mediated AA mobilization by cPLA 2 in intestinal myofibroblasts, and (iii) that activation of PAR-2 may stimulate proliferation of intestinal myofibroblasts by a cPLA 2 dependent mechanism. Based on these results, we hypothesize that TNF-α -induced PAR-2 up-regulation and PAR-2-mediated cPLA 2 activation might contribute to the intestinal myofibroblast proliferation associated with stricture formation in CD. However, further experimental work will be needed to investigate the effect of TNF-α on PAR-2 stimulated myofibroblast proliferation, and to elucidate which specific PLA 2 -derived lipid mediators mediate the proliferative effect upon PAR-2 stimulation. Moreover, to better mimic the in vivo situation, future studies should include studies on primary myofibroblasts isolated from patients, as well as studies on combinations of cytokines and growth factors found in the CD mucosa. One growth factor of particular interest might be TGFß 1 , since this factor is of prime importance in CD fibrogenesis, 58 has been shown to increase the expression of PAR-2 in myofibroblasts of extraintestinal origin, 59, 60 and also might be an inducer of PAR-2 cleaving proteases in the intestine. 61, 62 logical evaluation of the cryosections from CD specimens, and biomedical analyst Eva Sjödahl (Linköping University, Dept. of Clinical and Experimental Medicine) for help with the cryosectioning.
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